Oragenics Stock Forum

$Oragenics (OGEN.US)$ Oragenics, Inc. (NYSE American: OGEN) Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing -  Oragenics, Inc., a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced its lead candidate for treating concussion successfully completed a study that indicates ONP-002 does not cause cardiotoxicity. ONP-002 is a new chemical entity (NCE) designed to target the brain through del...

$Oragenics (OGEN.US)$ On Thursday, Oragenics Inc. (NYSE:OGEN) announced that its lead candidate for treating concussion completed a study that indicates ONP-002 does not cause cardiotoxicity.

$Oragenics (OGEN.US)$ Common causes of concussions include falls, motor vehicle accidents, and contact sports.
According to the CDC, the total annual healthcare cost for nonfatal traumatic brain injuries (TBIs) exceeds $40.6 billion

$Oragenics (OGEN.US)$ Before conducting a clinical trial, the FDA requires pharmaceuticals to be tested on cardiac receptors to ensure that they do not show any causes of electrical malformations.Based on Phase 1 ONP-002 clinical trial dosing and subsequent blood plasma concentrations, ONP-002 is expected to have a large cardiac safety margin, suggesting that ONP-002 treatment for concussion will not cause cardiac arrhythmia (irregular heartbeat).

$Oragenics (OGEN.US)$ Concussion, a mild traumatic brain injury that affects brain function, is a significant unmet medical need, with an estimated 69 million cases reported annually worldwide

$Oragenics (OGEN.US)$
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
Oragenics Inc. (NYSE American: OGEN) has announced that its lead candidate for treating concussion, ONP-002, has successfully completed FDA-required cardiotoxicity testing. The drug showed no signs of causing cardiac arrhythmia, demonstrating a strong safety margin for the heart. This clearance allows Oragenics to proceed with planning Phase II clinical trials for c...

$Oragenics (OGEN.US)$
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
Oragenics (NYSE American: OGEN) has announced the development of an automated intranasal device for treating concussed patients. The new prototype is designed for initial use in acute settings where patients are confused, dazed, or unconscious. Oragenics' lead drug candidate, ONP-002, aims to target the brain through nasal delivery. A Phase II study will evaluate ONP-002's effectiveness on blo...

$Oragenics (OGEN.US)$
Oragenics, Inc. Announces Closing of Public Offering
Oragenics announced the closing of its public offering of 1,100,000 shares at $1.00 per share, raising approximately $1.1 million. The funds will support the development of their ONP-002 product candidate and cover general corporate expenses. Dawson James Securities acted as the sole placement agent, and the offering was made under a shelf registration statement filed with the SEC. Legal representation was provided by ...

$Oragenics (OGEN.US)$
Oragenics, Inc. Announces Proposed Public Offering
Oragenics, Inc. (NYSE: OGEN), a company focused on intranasal pharmaceuticals for neurological disorders, announced a proposed public offering of its common stock or pre-funded warrants.
All securities in the offering will be sold by Oragenics. The proceeds will fund the development of its ONP-002 product candidate and cover general corporate expenses. Dawson James Securities, Inc. will serve as the sole placement agen...

$Oragenics (OGEN.US)$ why halted ?